SCHEMBL708522

SCHEMBL708522

FC(F)(F)Oc1cccc(CNCC2C3CN(Cc4cccc(OC(F)(F)F)c4)CC23)c1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 3/20 0.50
PRMT6 Q96LA8 3/20 0.50
DRD4 P21917 2/20 0.47
CHRM3 P20309 2/20 0.43
BACE1 P56817 3/20 0.43
CTSD P07339 1/20 0.43
CXCR3 P49682 1/20 0.43
OPRM1 P35372 1/20 0.42
CHRM4 P08173 1/20 0.42
SLC6A9 P48067 1/20 0.41
KCNH2 Q12809 1/20 0.41
BCHE P06276 2/20 0.41
ACHE P22303 2/20 0.41
TEAD1 P28347 1/20 0.41
DRD2 P14416 1/20 0.41
HCRTR1 O43613 1/20 0.40
HCRTR2 O43614 1/20 0.40
MAPK14 Q16539 1/20 0.40
NAMPT P43490 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15967105 0.95 CARM1 (0.46) CARM1PRMT6DRD4CHRM3BACE1
SCHEMBL712568 0.94 BACE1 (0.48) CARM1PRMT6DRD4CHRM3BACE1
SCHEMBL15967034 0.94 CXCR4 (0.46) CARM1PRMT6DRD4CHRM3BACE1
SCHEMBL15966997 0.94 CARM1 (0.48) CARM1PRMT6DRD4CHRM3BACE1
SCHEMBL5506387 0.93 HDAC3 (0.46) CARM1PRMT6DRD4CHRM3BACE1
SCHEMBL5512185 0.92 CARM1 (0.48) CARM1PRMT6DRD4BACE1CTSD
SCHEMBL5514667 0.92 CARM1 (0.46) CARM1PRMT6DRD4CHRM3BACE1
SCHEMBL5514659 0.92 CARM1 (0.46) CARM1PRMT6DRD4CHRM3BACE1
SCHEMBL5510930 0.92 CARM1 (0.46) CARM1PRMT6DRD4BACE1CTSD
SCHEMBL15967011 0.92 CARM1 (0.48) CARM1PRMT6DRD4BACE1CTSD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1869019-B1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS PFIZER PROD INC (US) 2014-08-27 EP claimed
EP-1869019-A1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS Pfizer Products Incorporated (US) 2007-12-26 EP claimed
WO-2006106425-A1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS PFIZER PRODUCTS INC. (US) 2006-10-12 WO claimed
EP-1869019-B1 BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS PFIZER PROD INC (US) 2014-08-27 EP disclosed
US-8124639-B2 Bicyclic [3.1.0] heteroaryl amides as type 1 glycine transport inhibitors PFIZER INC. (US) 2012-02-28 US disclosed
US-20100324020-A1 Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors PFIZER INC. 2010-12-23 US disclosed
US-20060229455-A1 Bicyclic [3.1.0.] heteroaryl amides as type 1 glycine transport inhibitors PFIZER INC. 2006-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324020-A1 Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors SLC1A2, SLC1A1, SLC6A5 CARM1 2561/4885PRMT6 1238/4885DRD4 468/4885
US-20060229455-A1 Bicyclic [3.1.0.] heteroaryl amides as type 1 glycine transport inhibitors SLC1A2, SLC1A1, GLRA1 CARM1 2205/4885PRMT6 1218/4885DRD4 476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.